BR112012009423A2 - método de alívio de crescimento de cãncer ou de um simtoma de cãncer, método de sensibilização de ccâncer a fármacos quimioterápicos, método de sensibilização de câncer à radioterapia e pacote de refeição terapêutica para fornecer refeições para um paciente com cãncer que retarda crescimento de cãncer e intensifica a eficácia de fármacos quimioterápicos - Google Patents

método de alívio de crescimento de cãncer ou de um simtoma de cãncer, método de sensibilização de ccâncer a fármacos quimioterápicos, método de sensibilização de câncer à radioterapia e pacote de refeição terapêutica para fornecer refeições para um paciente com cãncer que retarda crescimento de cãncer e intensifica a eficácia de fármacos quimioterápicos

Info

Publication number
BR112012009423A2
BR112012009423A2 BR112012009423A BR112012009423A BR112012009423A2 BR 112012009423 A2 BR112012009423 A2 BR 112012009423A2 BR 112012009423 A BR112012009423 A BR 112012009423A BR 112012009423 A BR112012009423 A BR 112012009423A BR 112012009423 A2 BR112012009423 A2 BR 112012009423A2
Authority
BR
Brazil
Prior art keywords
cancer
growth
sensitization method
chemotherapy
intensifies
Prior art date
Application number
BR112012009423A
Other languages
English (en)
Portuguese (pt)
Inventor
Lee Changhan
D Longo Valter
Original Assignee
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southern California filed Critical Univ Southern California
Publication of BR112012009423A2 publication Critical patent/BR112012009423A2/pt

Links

Classifications

    • GPHYSICS
    • G06COMPUTING OR CALCULATING; COUNTING
    • G06QINFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q10/00Administration; Management
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L13/00Meat products; Meat meal; Preparation or treatment thereof
    • A23L13/60Comminuted or emulsified meat products, e.g. sausages; Reformed meat from comminuted meat product
    • A23L13/65Sausages
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23PSHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P20/00Coating of foodstuffs; Coatings therefor; Making laminated, multi-layered, stuffed or hollow foodstuffs
    • A23P20/20Making of laminated, multi-layered, stuffed or hollow foodstuffs, e.g. by wrapping in preformed edible dough sheets or in edible food containers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07Retinol compounds, e.g. vitamin A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/375Ascorbic acid, i.e. vitamin C; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Business, Economics & Management (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Operations Research (AREA)
  • Entrepreneurship & Innovation (AREA)
  • Quality & Reliability (AREA)
  • Strategic Management (AREA)
  • Tourism & Hospitality (AREA)
  • Physics & Mathematics (AREA)
  • General Business, Economics & Management (AREA)
  • General Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • Human Resources & Organizations (AREA)
  • Marketing (AREA)
  • Economics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112012009423A 2009-10-22 2010-10-22 método de alívio de crescimento de cãncer ou de um simtoma de cãncer, método de sensibilização de ccâncer a fármacos quimioterápicos, método de sensibilização de câncer à radioterapia e pacote de refeição terapêutica para fornecer refeições para um paciente com cãncer que retarda crescimento de cãncer e intensifica a eficácia de fármacos quimioterápicos BR112012009423A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25415409P 2009-10-22 2009-10-22
PCT/US2010/053821 WO2011050302A2 (en) 2009-10-22 2010-10-22 Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment

Publications (1)

Publication Number Publication Date
BR112012009423A2 true BR112012009423A2 (pt) 2017-06-13

Family

ID=43900993

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012009423A BR112012009423A2 (pt) 2009-10-22 2010-10-22 método de alívio de crescimento de cãncer ou de um simtoma de cãncer, método de sensibilização de ccâncer a fármacos quimioterápicos, método de sensibilização de câncer à radioterapia e pacote de refeição terapêutica para fornecer refeições para um paciente com cãncer que retarda crescimento de cãncer e intensifica a eficácia de fármacos quimioterápicos

Country Status (13)

Country Link
US (2) US20110118528A1 (https=)
EP (1) EP2490684B1 (https=)
JP (1) JP2013508411A (https=)
CN (1) CN102753162A (https=)
AU (2) AU2010310515B2 (https=)
BR (1) BR112012009423A2 (https=)
CA (1) CA2779282C (https=)
DK (1) DK2490684T3 (https=)
ES (1) ES2659353T3 (https=)
PL (1) PL2490684T3 (https=)
PT (1) PT2490684T (https=)
RU (1) RU2549954C2 (https=)
WO (1) WO2011050302A2 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2888811C (en) * 2012-10-22 2023-10-24 University Of Southern California A diet package, and uses thereof
CN114236130A (zh) * 2013-02-12 2022-03-25 南加利福尼亚大学 用于减轻年龄相关症状的膳食包装
US9386790B2 (en) * 2013-07-01 2016-07-12 University Of Southern California Fasting condition as dietary treatment of diabetes
US10172839B2 (en) 2014-03-06 2019-01-08 University Of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
WO2015134837A2 (en) * 2014-03-06 2015-09-11 University Of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
CA2944088C (en) * 2014-03-28 2022-06-21 L-Nutra Inc. Tyrosine kinase inhibitors for use in a method of treating cancer in association with a reduced caloric intake
EP3125904A4 (en) * 2014-04-02 2017-08-30 University of Southern California Autoimmunity and multiple sclerosis treatment
KR20180002677A (ko) * 2015-04-16 2018-01-08 유니버시티 오브 써던 캘리포니아 라파마이신 및 덱사메타손에 의해 유도된 표준 및 고 글루코스 조건에 대응하여 정상 세포를 보호하고 암 감작 조건을 생성하는 금식 모방 규정식(fmd) 및 글루코스 저하 약물
BR112017023748A2 (pt) 2015-05-06 2018-07-31 University Of Southern California métodos para tratar hipertensão; reduzir níveis de colesterol elevados e/ou níveis de ldl elevados; reduzir níveis de triglicerídeo elevados e/ou níveis de crp elevados; tratar um indivíduo com níveis de insulina ou glicose elevados; tratar obesidade abdominal; tratar um indivíduo com níveis de igf-1 elevados; tratar ou prevenir inflamação; aumentar regeneração; e reduzir fígado gorduroso
RU2018114459A (ru) * 2015-09-21 2019-10-23 Ифом Фондационе Иституто Фирк Ди Онколоджа Молеколаре Новые стратегии лечения рака крови
CN108463121A (zh) * 2016-01-12 2018-08-28 南加利福尼亚大学 长期禁食模仿作为多发性骨髓瘤和其它癌症的膳食治疗的用途
KR20180120153A (ko) 2016-02-15 2018-11-05 유니버시티 오브 써던 캘리포니아 당뇨병 및 기타 질환 치료를 위한 배아형 재생을 자극하는 약물 조합물 및 방법
US12042477B2 (en) * 2016-02-23 2024-07-23 Cancer Research Technology Limited Dietary product devoid of at least two non essential amino acids
AU2017261723B2 (en) 2016-05-11 2023-02-09 University Of Southern California Fasting mimicking diet (FMD) as an immunoregulatory treatment for gastrointestinal autoimmune/inflammatory diseases.
IT201700008499A1 (it) * 2017-01-26 2018-07-26 Univ Degli Studi Genova Composizione dietetica per la prevenzione e/o il trattamento dell’iperplasia dell’endometrio
US11284640B2 (en) 2017-02-14 2022-03-29 University Of Southern California Fasting mimicking diet
CN107951892A (zh) * 2018-01-19 2018-04-24 丽水学院 锌原卟啉在制备增强人结直肠癌细胞对5-氟尿嘧啶化疗敏感性药物中的应用
MX2020009613A (es) 2018-03-15 2021-02-26 Univ Southern California Dieta que imita el ayuno (fmd) pero no ayuno solo con agua, promueve la reversion de la inflamacion y patologia de la enfermedad de intestino irritable (ibd).
WO2020015842A1 (en) * 2018-07-18 2020-01-23 Michalsen Andreas Effects of a short-term fasting mimicking diet on quality of life and tolerance to chemotherapy in patients with cancer
CA3119100C (en) 2018-11-09 2024-06-04 Valter D. Longo Nutrition bar for intermittent fasting-mimicking
CA3134756A1 (en) 2019-04-30 2020-11-05 Valter D. Longo Fasting-mimicking diet (fmd) as an intervention for alzheimer's disease (ad)
JP6747702B1 (ja) * 2019-05-10 2020-08-26 株式会社医療情報技術研究所 栄養処方管理システム
PH12021552866A1 (en) 2019-05-14 2022-11-07 Tyme Inc Compositions and methods for treating cancer
IT201900009954A1 (it) * 2019-06-24 2020-12-24 Fondazione Irccs Istituto Naz Dei Tumori Preparazione alimentare a basso contenuto calorico per l’alimentazione di pazienti affetti da neoplasie
WO2021118324A1 (ko) * 2019-12-13 2021-06-17 서울대학교산학협력단 암의 예방 또는 치료용 약학 조성물
IT202000007153A1 (it) 2020-04-03 2021-10-03 Ifom Fondazione St Firc Di Oncologia Molecolare Apporto calorico ridotto e immunoterapia per il trattamento del cancro
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections
US12220402B2 (en) 2020-06-03 2025-02-11 Faeth Therapeutics, Inc. Formulations for personalized methods of treatment
WO2021247923A1 (en) 2020-06-04 2021-12-09 Faeth Therapeutics, Inc. Personalized methods of treating cancer
TW202227113A (zh) * 2020-12-01 2022-07-16 南加州州立大學 模擬禁食飲食提升急性淋巴母細胞白血病模型中的無癌存活
US20240000125A1 (en) * 2020-12-17 2024-01-04 Fondazione Irccs Istituto Nazionale Dei Tumori Diet preparation for the nutrition of cancer patients with a restricted calorie intake
EP4066823B1 (en) 2021-03-30 2025-04-30 IFOM - Istituto Fondazione di Oncologia Molecolare ETS Reduced caloric intake and anticancer agents for the treatment of cancer
CN115590963A (zh) * 2022-07-13 2023-01-13 复旦大学(Cn) 酮体、酮体诱导剂和生酮组合物中的至少一种在治疗和/或预防血小板减少症药物中的应用
EP4599826A1 (en) 2024-02-06 2025-08-13 IFOM - Istituto Fondazione di Oncologia Molecolare ETS Leucine for use in the treatment of cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2074731C1 (ru) * 1994-12-29 1997-03-10 Игорь Александрович Бойко Фитокомплекс, обладающий противоопухолевым действием, и способ лечения онкологических больных
CN1315473C (zh) * 1997-03-17 2007-05-16 英国技术集团国际有限公司 治疗组合物
AU5319499A (en) * 1999-07-22 2001-02-13 Ivan L. Cameron Fatty acids to minimize cancer therapy side effects
JP4625156B2 (ja) * 2000-04-10 2011-02-02 イーエヌ大塚製薬株式会社 癌化学療法に伴う副作用軽減剤
WO2005117542A2 (en) * 2004-05-10 2005-12-15 Novacea, Inc. Treatment of pancreatic cancer with active vitamin d compounds in combination with other treatments
WO2006043966A2 (en) * 2004-10-15 2006-04-27 University Of Tennessee Research Foundation Methods for inducing apoptosis in adipocytes
US20070116802A1 (en) * 2005-11-23 2007-05-24 Carl Germano High quality caloric composition
US20080038367A1 (en) * 2006-08-11 2008-02-14 Sal Saloum Nutritional supplement compositions and methods of preparing
RU2354369C2 (ru) * 2007-03-16 2009-05-10 Михаил Владимирович Кутушов Применение родамина 6ж в качестве лекарственного средства для лечения злокачественных новообразований и амилоидозов
EP2156188B1 (en) * 2007-03-28 2021-05-05 University of Southern California Induction of differential stress resistance and uses thereof
CA2706656A1 (en) * 2007-11-26 2009-06-04 Nestec S.A. Compositions and methods for inhibiting the activation of dsrna-dependent protein kinase and tumor growth inhibition

Also Published As

Publication number Publication date
AU2010310515A1 (en) 2012-05-17
EP2490684B1 (en) 2018-01-03
JP2013508411A (ja) 2013-03-07
US20110118528A1 (en) 2011-05-19
PT2490684T (pt) 2018-04-02
US20210209516A1 (en) 2021-07-08
ES2659353T3 (es) 2018-03-14
RU2012118588A (ru) 2013-11-27
AU2016201607A1 (en) 2016-03-31
RU2549954C2 (ru) 2015-05-10
PL2490684T3 (pl) 2018-07-31
DK2490684T3 (en) 2018-04-09
EP2490684A4 (en) 2016-05-04
WO2011050302A3 (en) 2011-08-25
AU2016201607B2 (en) 2017-11-30
CA2779282A1 (en) 2011-04-28
WO2011050302A2 (en) 2011-04-28
AU2010310515B2 (en) 2016-01-07
CA2779282C (en) 2017-12-05
CN102753162A (zh) 2012-10-24
EP2490684A2 (en) 2012-08-29

Similar Documents

Publication Publication Date Title
BR112012009423A2 (pt) método de alívio de crescimento de cãncer ou de um simtoma de cãncer, método de sensibilização de ccâncer a fármacos quimioterápicos, método de sensibilização de câncer à radioterapia e pacote de refeição terapêutica para fornecer refeições para um paciente com cãncer que retarda crescimento de cãncer e intensifica a eficácia de fármacos quimioterápicos
BR112013011480A2 (pt) método de tratamento de câncer, método de aumento da eficácia terapêutica de uma droga anticâncer, pmo1183 ou um sal farmaceuticamente aceitável do mesmo, uso do mesmo e kit para uso no tratamento de câncer
BR112012000862A8 (pt) composição farmacêutica oral, composição farmacêutica oral de baixa dose para administração crônica, método de tratamento ou retardo do inicio ou desenvolvimento de uma condição, método de tratamento da dor em um indivíduo que necessita deste medicamento, método de tratamento de uma condição em um indivíduo que necessita deste medicamento
AR124500A2 (es) Aumento de la biodisponibilidad de droga en terapia naltrexona
BR112012017150A2 (pt) formulação de anticorpo e regimes terapêuticos.
PL3599237T3 (pl) Kompozycja farmaceutyczna inhibitora syntazy glukozyloceramidowej eliglustatu do leczenia choroby Gauchera obejmującego dostosowanie indywidualnej dawki terapeutycznej do metabolizmu P450 pacjenta
BR112015023910A2 (pt) terapia envolvendo anticorpos contra claudin 18.2 para tratamento de câncer
BRPI0813402A2 (pt) Agente para evitar ou tratar um câncer resistente a trastuzumab, droga combinada, métodos para prevenir ou tratar câncer resistente a trastuzumab, para examinar a sensibilidade de um câncer expressando her2 a um inibidor de her2, para tratar um câncer em um animal julgado ter baixa sensibilidade a um inibidor de her2 e para triar uma droga para a profilaxia ou tratamento de um câncer resistente a trastuzumab, e, uso de um ou mais medicamentos.
BRPI0813513A2 (pt) Terapia específica e medicamento usando ligantes de integrina para tratamento de câncer
ES2425315R1 (es) Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento sintomático de una enfermedad o afección respiratoria
BR112015006656A8 (pt) composições e métodos para o tratamento de insuficiência cardíaca em pacientes diabéticos
BR112014018450A8 (pt) Fenilimidazopirazoles substituídos e sua utilização
DeLeve Cancer chemotherapy
MX2022000394A (es) Combinaciones terapeuticas de paclitaxel oralmente administrado y un inhibidor de la bomba de p-glicoproteina (p-gp) para el tratamiento del cancer.
Theyab et al. Angiotensin-converting enzyme inhibitor-induced angioedema
Lee et al. A phase II open label trial of PF-00299804 monotherapy in patients with HER-2 positive advanced gastric cancer after failure of at least one prior chemotherapy regimen
Fabiny Ask the doctor. I have just stopped taking a statin drug because it was causing muscle pain. To control my cholesterol I'm now taking ground flaxseed and a daily red yeast rice pill. Are these supplements effective for lowering cholesterol?
Carew et al. Targeting HDAC6 Is a novel approach to augment the therapeutic benefit of bromodomain inhibition in multiple myeloma
Gola Various toxicities: 12 case reports
Celona et al. 1030–Ocular pigmentation and cataract in therapy with phenothiazine
Yu Application of reiki on depression in nursing: a literature review
Park et al. Clinical Features and Treatment Outcomes of Primary Testicular Lymphoma.
Allameh et al. Clinical pharmacists’ interventions in a teaching hospital: types, severity, procedures, and accuracy
ES2446215R2 (es) Aplicación terapéutica de agentes inhibidores de cd44 frente a la leucemia linfoblástica aguda (all) humana.
Pulla et al. Consolidation treatment with y90-ibritumomab tiuxetan after r-chop induction in high-risk patients with follicular lymphoma (FL)(GOTEL-FL1LC): A multicentric, prospective study

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL

B350 Update of information on the portal [chapter 15.35 patent gazette]